Market Intelligence, Clinical Progress, and High-Purity Reagents for Chronic Cough and Pain Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for P2RX3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | P2RX3 Lentivirus Premade Particles Full-length ORF for stable cell line construction. HEK293T packaged, titer >10^8 TU/mL. Sequence Verified. |
View P2RX3 Products |
| Antigen | P2RX3 ECD Protein (Human/Cyno/Mouse orthologs) and Mutant Protein (rs2276038) >95% purity, Endotoxin <1EU/μg. Theoretical MW verified. |
View P2RX3 Products |
| Benchmark Ab | Anti-P2RX3 Reference Antibody Recombinant monoclonal positive control for assay validation. |
View P2RX3 Products |
| Validator | P2RX3 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View P2RX3 Products |
| Heteromer Partner | P2RX2 Forms P2X2/3 heterotrimeric channels. Critical for selectivity screening to avoid taste disturbance. |
View P2RX2 Products |
| Pathway Regulator | ENPP1 (CD39) Ectonucleotidase regulating extracellular ATP levels. Synergistic target in pain and inflammation. |
View ENPP1 Products |
| Synergistic Target | TRPV1 Involved in neurogenic inflammation and cough reflex. |
View TRPV1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heteromer vs Homomer Selectivity (P2X2/3 vs P2X3) | P2RX3 and P2RX2 ortholog proteins strictly verified by mass spec for cross-reactivity panels |
| Cross-species Cyno/Mouse/Rat Evaluation | Human/Cyno/Mouse P2RX3 lentivirus and proteins with >95% sequence homology coverage |
| State-dependent Binding (Open vs Closed Channel) | Stable cell lines generated from sequence-verified lentivirus for live-cell electrophysiology |
| False Positives in Calcium Flux | Validated siRNA included for specificity checks and target engagement verification |
| Conformational Integrity of Ion Channel | Premade Lentivirus for robust HEK293/CHO stable cell line generation (Calcium Flux/Patch Clamp ready) |
Live P2RX3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Antagonist Research
- ➤ Chronic Cough Mechanism Studies
- ➤ Resistance and Variant Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for P2RX3 therapeutics has shifted from broad neuropathic pain to specific indications with clear mechanistic drivers, particularly refractory chronic cough and visceral pain. Following the regulatory setbacks of first-generation small molecule antagonists (e.g., gefapixant) due to P2X2/3 heteromer-mediated taste disturbance, the field is pivoting toward highly selective homotrimer compounds and biologics with improved therapeutic indices. Second-generation state-dependent antagonists and monoclonal antibodies are entering the clinic, focusing on heterotrimer selectivity and peripheral restriction to minimize CNS liabilities. Notably, the missense variant rs2276038 (Val70Ile) in P2RX3 has been associated with altered channel function and may affect drug binding; screening against this variant is increasingly important for clinical candidate selection.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Bayer, Bellus Health, Shionogi, Merck | Refractory Chronic Cough, Endometriosis Pain | State-dependent electrophysiology (Need stable P2RX3-expressing cell lines via lentivirus) |
| Monoclonal Antibody | Confo Therapeutics | Visceral Pain, Neuropathic Pain | Heterodimer validation (Need P2RX2/3 co-expression systems) |
| Allosteric Modulator | Academic/Early Biotech | Inflammatory Pain, Visceral Hypersensitivity | Binding site mapping (Need mutant panels for orthosteric vs allosteric sites) |
| Peptide Inhibitors | Academic/Biotech | Visceral hypersensitivity | Calcium Flux validation (Need high-titer Lentivirus delivery) |
Key Mutations and Variants
- rs2276038 (Val70Ile): A missense variant in the extracellular domain of P2RX3. Evidence from UniProt (VAR_034674) indicates this polymorphism may alter receptor desensitization kinetics and ATP sensitivity. Drug discovery programs should evaluate compound activity against this variant to ensure broad clinical applicability.
Future Outlook
The next wave of P2RX3 therapeutics will hinge on:
- High selectivity against P2RX2/3 heterotrimers (>100-fold)
- State-dependent inhibition (open vs. desensitized)
- Peripheral restriction to avoid CNS side effects
- Cross-species validation (human, cynomolgus monkey, rat)
- Incorporation of known genetic variants (rs2276038) into screening panels
TarMart's integrated reagent suite—combining lentivirus, proteins, antibodies, and siRNA—enables researchers to address these challenges efficiently.